AG Deals Not Outlawed by 3rd Circuit’s Anti Pay-for-Delay Stance: Lower Court

January 7, 2013
A New Jersey court has thrown out an antitrust lawsuit against Teva and GlaxoSmithKline, ruling that patent settlements that involve authorized generic agreements are not illegal. Authorized generic deals would not be considered “reverse payments” under the 3rd Circuit’s July K-Dur decision, says the district court, which falls under that circuit’s jurisdiction.
Generic Line